283 related articles for article (PubMed ID: 2458208)
21. [New option in the management of cancer pain in Hungary: short acting oral opioid therapy].
Kullmann T; Sipőcz I; Csikós Á; Pintér T
Orv Hetil; 2015 Jun; 156(25):1003-6. PubMed ID: 26170088
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder.
Dong R; Wang H; Li D; Lang L; Gray F; Liu Y; Laffont CM; Young M; Jiang J; Liu Z; Learned SM
Drugs R D; 2019 Sep; 19(3):255-265. PubMed ID: 31197606
[TBL] [Abstract][Full Text] [Related]
23. Assessment of the trends in medical use and misuse of opioid analgesics from 2004 to 2011.
Atluri S; Sudarshan G; Manchikanti L
Pain Physician; 2014; 17(2):E119-28. PubMed ID: 24658483
[TBL] [Abstract][Full Text] [Related]
24. Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series.
Nielsen S; Bruno R; Degenhardt L; Demirkol A; Lintzeris N
Drug Alcohol Rev; 2017 May; 36(3):311-316. PubMed ID: 27273511
[TBL] [Abstract][Full Text] [Related]
25. Oral diacetylmorphine (heroin) yields greater morphine bioavailability than oral morphine: bioavailability related to dosage and prior opioid exposure.
Halbsguth U; Rentsch KM; Eich-Höchli D; Diterich I; Fattinger K
Br J Clin Pharmacol; 2008 Dec; 66(6):781-91. PubMed ID: 18945270
[TBL] [Abstract][Full Text] [Related]
26. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
27. The Conversion Ratio From Intravenous Hydromorphone to Oral Opioids in Cancer Patients.
Reddy A; Vidal M; Stephen S; Baumgartner K; Dost S; Nguyen A; Heung Y; Kwan S; Wong A; Pangemanan I; Azhar A; Tayjasanant S; Rodriguez E; Waletich J; Lim KH; Wu J; Liu D; Williams J; Yennurajalingam S; Bruera E
J Pain Symptom Manage; 2017 Sep; 54(3):280-288. PubMed ID: 28711751
[TBL] [Abstract][Full Text] [Related]
28. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites.
Smith MT
Clin Exp Pharmacol Physiol; 2000 Jul; 27(7):524-8. PubMed ID: 10874511
[TBL] [Abstract][Full Text] [Related]
29. Opioid plasma concentrations during a switch from transdermal fentanyl to methadone.
Mercadante S; Villari P; Ferrera P; Casuccio A; Gambaro V
J Palliat Med; 2007 Apr; 10(2):338-44. PubMed ID: 17472504
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the clearance of a sublingual buprenorphine spray in the beagle dog using gamma scintigraphy.
McInnes F; Clear N; James G; Stevens HN; Vivanco U; Humphrey M
Pharm Res; 2008 Apr; 25(4):869-74. PubMed ID: 17763831
[TBL] [Abstract][Full Text] [Related]
31. Contribution to variability in response to opioids.
Hanks GW; Reid C
Support Care Cancer; 2005 Mar; 13(3):145-52. PubMed ID: 15761703
[TBL] [Abstract][Full Text] [Related]
32. The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine.
Lim SCB; Schug S; Krishnarajah J
Pain Med; 2019 Jan; 20(1):143-152. PubMed ID: 29309700
[TBL] [Abstract][Full Text] [Related]
33. A phase I pharmacokinetic and bioavailability study of a sublingual fentanyl wafer in healthy volunteers.
Lim CB; Schug SA; Sunderland VB; Paech MJ; Liu Y
Anesth Analg; 2012 Sep; 115(3):554-9. PubMed ID: 22584544
[TBL] [Abstract][Full Text] [Related]
34. Opioid analgesics-related pharmacokinetic drug interactions: from the perspectives of evidence based on randomized controlled trials and clinical risk management.
Feng XQ; Zhu LL; Zhou Q
J Pain Res; 2017; 10():1225-1239. PubMed ID: 28579821
[TBL] [Abstract][Full Text] [Related]
35. Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations.
Nath RP; Upton RA; Everhart ET; Cheung P; Shwonek P; Jones RT; Mendelson JE
J Clin Pharmacol; 1999 Jun; 39(6):619-23. PubMed ID: 10354966
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of Single Doses of Methadone and Buprenorphine in Blood and Oral Fluid in Healthy Volunteers and Correlation With Effects on Psychomotor and Cognitive Functions.
Strand MC; Ramaekers JG; Gjerde H; Mørland J; Vindenes V
J Clin Psychopharmacol; 2019; 39(5):489-493. PubMed ID: 31305338
[TBL] [Abstract][Full Text] [Related]
37. Sublingual and oral morphine administration. Review and new findings.
Robison JM; Wilkie DJ; Campbell B
Nurs Clin North Am; 1995 Dec; 30(4):725-43. PubMed ID: 7501539
[TBL] [Abstract][Full Text] [Related]
38. A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients.
Nosek K; Leppert W; Nosek H; Wordliczek J; Onichimowski D
Drug Des Devel Ther; 2017; 11():2409-2419. PubMed ID: 28860712
[TBL] [Abstract][Full Text] [Related]
39. Sublingual morphine: efficacy reviewed.
Coluzzi PH
J Pain Symptom Manage; 1998 Sep; 16(3):184-92. PubMed ID: 9769621
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone.
Sekar V; Tomaka F; Lefebvre E; De Pauw M; Vangeneugden T; van den Brink W; Hoetelmans R
J Clin Pharmacol; 2011 Feb; 51(2):271-8. PubMed ID: 20421512
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
